COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) is the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. The COVID-19 EIA/ELISA pipeline product report provides comprehensive information about the pipeline products with comparative analysis at various stages of development and information about the clinical trials which are in progress. The report also provides key information and clinical trial data regarding ongoing clinical trials such as trial phase, trial status, trial start and end dates, and the number of trials of the major COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline products.
Which are the key territories covered in the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline product market?
The US accounts for the highest number of COVID-19 EIA/ELISA pipeline products in the market followed by Canada and Europe. The other top territories include India, China, Australia, Brazil, Japan, Taiwan, the UK, Argentina, Mexico, New Zealand, Singapore, South Africa, South Korea, Chile, Colombia, Costa Rica, Ecuador, and El Salvador.
COVID-19 EIA/ELISA pipeline product market, by territory
For more regional insights, download a free report sample
What are the different stages of development in the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline product market?
The maximum number of pipeline products in the market is in the approval process. More than 50 are in the clinical process and over 40 are in the early development process. EUA is the most popular regulatory path taken for the approval of enzyme immuno EIA/ELISA pipeline products. As of November 2021, it has been estimated that by 2022, one of the pipeline products will be approved.
COVID-19 EIA/ELISA pipeline product market, by stage of development
For more stage of development insights, download a free report sample
Which are the major companies in the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline product market?
The key companies in the COVID-19 EIA/ELISA pipeline product market are 20/20 GeneSystems Inc, Abbott Diagnostics, Abbott Laboratories, Absology Co Ltd, Abwiz Bio Inc, Achira Labs Pvt Ltd, ADiTx Therapeutics Inc, ADMA Biologics Inc, AegirBio AB, Aegis Sciences Corp, Affigenix Biosolutions Pvt Ltd, Agilent Technologies Inc, ALPCO Diagnostics, Anhui Deep Blue Medical Technology Co Ltd, and Ansh Labs LLC.
20/20 GeneSystems Inc: It is a medical diagnostic company that discovers, develops, and commercializes proteomics products and diagnostic tests for therapy selection, early disease detection, and biodefense applications. It provides tests in the areas of early detection of lung cancer, personalized medicine, and biological detection. 20/20 Gene’s blood test technology is used in the early detection of lung cancer and provides a method for analysis of cell signaling in tissue and technologies to detect biological toxins. The company offers its products and services to drug companies, biodefense specialists, and life scientists for protein analysis.
Abbott Diagnostics: It is a subsidiary of Abbott Laboratories. The company manufactures in vitro diagnostic systems and tests. They offer various core laboratory products, molecular point of care products, transfusion medicine, professional services, and a diagnostics portfolio. Abbott products portfolio includes laboratory systems for automation molecular diagnostic systems and point of care systems for blood analysis. The company products find application in therapeutic drug monitoring, measurement of antibodies and antigens, and screening and diagnosis of cancer. Abbott serves blood banks, hospitals, commercial laboratories, government agencies, patient care testing sites, and plasma protein therapeutic companies.
Abbott Laboratories: They discover, develop, manufacture, and sell a diversified range of healthcare products including branded generic pharmaceuticals, diagnostic systems and tests, and pediatric and adult nutritional products. The company also offers various medical devices including heart failure, electrophysiology, rhythm management, vascular and structural heart devices, and neuromodulation devices. The company also offers minerals and nutrition products and various dietary supplements.
Absology Co Ltd: The company manufactures in vitro diagnostic systems and tests. Their product can be used to detect antibodies.
Abwiz Bio Inc: They are involved with manufacturing in vitro diagnostic systems. Their product can be applied for the diagnosis of Coronavirus disease.
COVID-19 EIA/ELISA pipeline product market, by company
To know more about key companies, download a free report sample
Market report scope
| Key territory | The US, Canada, Europe, India, China, Australia, Brazil, Japan, Taiwan, the UK, Argentina, Mexico, New Zealand, Singapore, South Africa, South Korea, Chile, Colombia, Costa Rica, Ecuador, and El Salvador |
| Key stages of development | Early Development, Pre-Clinical, Clinical, In-approval, Inactive, and Discontinued |
| Key regulatory path | EUA, CE-IVD, 510(k), MDL, TGA, and ANVISA |
| Key companies | 20/20 GeneSystems Inc, Abbott Diagnostics, Abbott Laboratories, Absology Co Ltd, Abwiz Bio Inc, Achira Labs Pvt Ltd, ADiTx Therapeutics Inc, ADMA Biologics Inc, AegirBio AB, Aegis Sciences Corp, Affigenix Biosolutions Pvt Ltd, Agilent Technologies Inc, ALPCO Diagnostics, Anhui Deep Blue Medical Technology Co Ltd, and Ansh Labs LLC |
This report provides an in-depth analysis of the following:
- Extensive coverage of the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) under development.
- Details of major pipeline products which include, product description, licensing and collaboration details, and other developmental activities.
- The major players involved in the development of COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) and list all their pipeline projects.
- The coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
- Key clinical trial data of ongoing trials specific to pipeline products.
- Recent developments in the segment/industry.
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Identify and understand important and diverse types of COVID 19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) under development.
- Develop market entry and market expansion strategies.
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
- In-depth analysis of the product’s current stage of development, territory, and estimated launch date.
Abbott Diagnostics
Abbott Laboratories
Absology Co Ltd
Abwiz Bio Inc
Achira Labs Pvt Ltd
ADiTx Therapeutics Inc
ADMA Biologics Inc
AegirBio AB
Aegis Sciences Corp
Affigenix Biosolutions Pvt Ltd
Agilent Technologies Inc
ALPCO Diagnostics
Anhui Deep Blue Medical Technology Co Ltd
Ansh Labs LLC
Arrayit Corp
ARUP Laboratories
Avacta Group Plc
Axim Biotechnologies Inc
Axium BioResearch Inc
Babson Diagnostics Inc
Base10 Genetics Inc
Beckman Coulter Inc
Beijing Shengkun Kangru Medical Equipment Co Ltd
Ben-Gurion University of the Negev
Biohit Healthcare Ltd
BioIQ Inc
Biolinker Synthetic Biology Ltd
Biomerica Inc
Bio-Techne Corp
BioVaxys Technology Corp
Bloom Diagnostics AG
Boston University
BreviTest Technologies LLC
Calviri Inc
Capricor Therapeutics Inc
CareHealth America Corp
Cellex Inc
Cellmid Ltd
Celltrion Inc
Core Technology Co Ltd
DiaCarta Inc
Diagnostics Biochem Canada Inc
DIALAB GmbH
DiaSorin SpA
Diazyme Laboratories Inc
DLS Research and Ventures
DRG International Inc
EDP Biotech Corporation
Empower Clinics Inc
Enable Biosciences Inc
Enzo Biochem Inc
Epigentek Group Inc
Epitope Diagnostics, Inc.
Eurobio Scientific SA
Eurofins Scientific SE
Euroimmun AG
Excelsior Bio-Systems Inc
Ezra AI Inc
Fujirebio Diagnostics Inc
General Biologicals Corp
Halberd Corp
Hecin Scientific Inc
Hunan Lituo Biotechnology Co Ltd
Icosagen AS
ICT International
IDvet
Immunodiagnostics Ltd
ImmunoPrecise Antibodies Ltd
Indian Institute of Technology Guwahati
Interpace Biosciences Inc
Kantaro Biosciences LLC
Kephera Diagnostics LLC
KRISHGEN BioSystems
Lansion Biotechnology Co Ltd
Leadgene Biomedical Inc
Leinco Technologies Inc
Liquid Diagnostics LLC
Lumos Diagnostics Inc
Maxim Biomedical Inc
Meridian Bioscience Inc
Module Innovations Pvt Ltd
Mologic Ltd
Monarch Global Health LLC
Monopar Therapeutics Inc
Nanjing Liming Bio-Products Co Ltd
NanoRepro AG
Nirmidas Biotech Inc
Northwestern University
Novacyt SA
NovaTec Immundiagnostica GmbH
Novo Nordisk AS
OraSure Technologies Inc
Ortho Clinical Diagnostics Holdings Plc
Oy Medix Biochemica Ab
P3 Diagnostics LLC
Pepex Biomedical, Inc.
PerkinElmer Inc
Pinnacle BioLabs
Prantae Solutions Pvt Ltd
Premier Medical Corporation
ProAxsis Ltd
ProGnosis Biotech SA
Promega Corp
ProMIS Neurosciences Inc
Qiagen NV
Qlife Holding AB
Quanterix Corp
Quotient Ltd
Randox Laboratories Ltd
Roche Diagnostics International Ltd
Safetest Comercio de Diagnosticos Ltd
Salofa Oy
ScheBo Biotech AG
Sciteck Diagnostics Inc
Shenzhen Kingfocus Biomedical Engineering Co Ltd
Shenzhen Tisenc Medical Devices Co Ltd
Shijiazhuang Hipro Biotechnology Co Ltd
Siemens Healthcare Diagnostics Inc
Siemens Healthineers AG
SQI Diagnostics Inc
St Petersburg Research Institute of Vaccines and Serums
Stream Bio Ltd
Syngene
Sysmex Corp
Taizhou ZECEN Biotech Co Ltd
The Binding Site Inc
ThermoGenesis Holdings Inc
Trinity College Dublin
University of Melbourne
VidaCheck LLC
VirIntel LLC
Vivera Pharmaceuticals Inc
Vyriad Inc
West Virginia University School of Medicine
Zalgen Labs LLC
Zandcell AB
ZRT Laboratory LLC
Table of Contents
Frequently asked questions
-
Which are the key territories covered in the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline product market?
The key countries in the COVID-19 EIA/ELISA pipeline product market are the US, Canada, Europe, India, China, Australia, Brazil, Japan, Taiwan, the UK, Argentina, Mexico, New Zealand, Singapore, South Africa, South Korea, Chile, Colombia, Costa Rica, Ecuador, and El Salvador.
-
What are the key stages of development in the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline products market?
The key stages of development in the COVID-19 EIA/ELISA pipeline product market are early development, pre-clinical, clinical, in-approval, inactive, and discontinued.
-
Which are the key companies in the COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay pipeline products market?
The key companies in the COVID-19 EIA/ELISA pipeline product market are 20/20 GeneSystems Inc, Abbott Diagnostics, Abbott Laboratories, Absology Co Ltd, Abwiz Bio Inc, Achira Labs Pvt Ltd, ADiTx Therapeutics Inc, ADMA Biologics Inc, AegirBio AB, Aegis Sciences Corp, Affigenix Biosolutions Pvt Ltd, Agilent Technologies Inc, ALPCO Diagnostics, Anhui Deep Blue Medical Technology Co Ltd, and Ansh Labs LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
